top of page

Developing selective
NLRP3 inflammasome inhibitors
for severe inflammatory diseases

stock-photo-molecular-structure-of-short-peptide-sequence-alanine-valine-asparagine-prolin

Science/Technology

Our drug discovery platform is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases including acute lung injury, ARDS, Bronchopulmonary Dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.  

 

Our lead candidate, AZM-152, is a small molecule, RHAMM-derived antagonist that blocks a key upstream priming signal involved in the aberrant activation of the NLRP3 inflammatory cascade.

Cloud Analytics Modernization

I'm a paragraph. Click here to add your own text and edit me. Let your users get to know you.

Versatility in Application

I'm a paragraph. Click here to add your own text and edit me. Let your users get to know you.

Data Science Acceleration

I'm a paragraph. Click here to add your own text and edit me. Let your users get to know you.

Full Customer Experience Service

I'm a paragraph. Click here to add your own text and edit me. Let your users get to know you.

Unprecedented Velocity. Impeccable Reliability.

Initial indications target severe inflammatory pulmonary diseases with significant unmet needs:

​

  • Acute Respiratory Distress Syndrome (ARDS)
     

  • Bronchopulmonary Dysplasia (BPD), a consequence of acute lung injury in preterm infants
     

  • Acute Exacerbations of Idiopathic Pulmonary Fibrosis (IPF)
     

  • Severe viral pneumonia such as Influenza A and COVID-19 infection

 

For many inflammatory and fibrotic lung diseases, no effective preventative or therapeutic treatments exist.  With limited options for disease management, these severe and acute lung conditions exert a considerable burden on patients, families, and healthcare providers, including higher rates of mortality, longer lengths of stay in intensive care units, and life-long morbidities.

 

Additional indications for clinical development include other NLRP3 inflammasome-mediated severe inflammatory diseases of the lungs, liver and kidneys.

We Take Pride in Our Numbers

15

Years of Experience

10K

Business Partners

25M

Products Installed

22

Countries World Wide

5

Industry Awards

Our Partners

Are You Ready to Accelerate Your Business?

I'm a paragraph. Click here to add your own text and edit me. It’s easy. Just click “Edit Text” or double click me to add your own content and make changes to the font. 

bottom of page